Sep 13, 2022 / 01:40PM GMT
Jeffrey D. Johnson - Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst
My name is Jeff Johnson. I'm the senior medical technology analyst at Baird. Our next presentation this morning is from Tandem Diabetes, a leader in the $3.5 billion global insulin pump market. With us today from Tandem, we're happy to have President and Chief Executive Officer, John Sheridan; as well as Chief Financial Officer, Leigh Vosseller.
John, I'll turn it over to you if you have a few prepared remarks, and then we'll just go into Q&A.
John F. Sheridan - Tandem Diabetes Care, Inc. - President, CEO & Director
Welcome, everybody. It's good to see you, Jeff. I think I wanted to start off by just clarifying some of the things that we said on the 2Q call. We indicated that we had experienced pressure in June and July from a variety of factors. And as we exit the month of August, what we have seen is we've seen a positive shift. And we think it's the beginning of the momentum build that lines up with the guidance that we gave during the
Tandem Diabetes Care Inc at Robert W Baird Global Healthcare Conference Transcript
Sep 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers